📣 VC round data is live. Check it out!

Boston Scientific Valuation Multiples

Discover revenue and EBITDA valuation multiples for Boston Scientific and similar public comparables like Medtronic, Stryker, Edwards Lifesciences, Siemens Healthineers and more.

Boston Scientific Overview

About Boston Scientific

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.


Founded

1979

HQ

United States

Employees

59.0K

Financials (LTM)

Revenue: $21B
EBITDA: $6B

EV

$93B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Boston Scientific Financials

Boston Scientific reported last 12-month revenue of $21B and EBITDA of $6B.

In the same LTM period, Boston Scientific generated $14B in gross profit, $6B in EBITDA, and $5B in net income.

Revenue (LTM)


Boston Scientific P&L

In the most recent fiscal year, Boston Scientific reported revenue of $20B and EBITDA of $5B.

Boston Scientific is profitable as of last fiscal year, with gross margin of 69%, EBITDA margin of 25%, and net margin of 14%.

See analyst estimates for Boston Scientific
LTMLast FY202320242025202620272028
Revenue$21B$20B$14B$17B$20B
Gross Profit$14B$14B$10B$11B$14B
Gross Margin70%69%69%69%69%
EBITDA$6B$5B$3B$4B$5B
EBITDA Margin31%25%24%23%25%
EBIT Margin28%20%17%18%20%
Net Profit$5B$3B$2B$2B$3B
Net Margin23%14%11%11%14%
Net Debt$9B

Financial data powered by Morningstar, Inc.

Boston Scientific Stock Performance

Boston Scientific has current market cap of $83B, and enterprise value of $93B.

Market Cap Evolution


Boston Scientific's stock price is $55.98.

Boston Scientific share price decreased by 2.8% in the last 30 days, and by 46.8% in the last year.

Boston Scientific has an EPS (earnings per share) of $1.95.

See more trading valuation data for Boston Scientific
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$93B$83B0.0%-2.8%-27.2%-46.8%$1.95

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Boston Scientific Valuation Multiples

Boston Scientific trades at 4.5x EV/Revenue multiple, and 14.4x EV/EBITDA.

See NTM and 2027E valuation multiples for Boston Scientific

EV / Revenue (LTM)


Boston Scientific Financial Valuation Multiples

As of May 7, 2026, Boston Scientific has market cap of $83B and EV of $93B.

Boston Scientific has a P/E ratio of 17.6x.

LTMLast FY202320242025202620272028
EV/Revenue4.5x4.6x6.5x5.5x4.6x
EV/EBITDA14.4x18.2x26.9x24.1x18.2x
EV/EBIT16.0x23.4x38.4x30.9x23.4x
EV/Gross Profit6.4x6.7x9.4x8.1x6.7x
P/E17.6x28.7x52.2x44.9x28.7x
EV/FCF24.8x27.3x54.5x39.2x27.3x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Boston Scientific Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Boston Scientific Margins & Growth Rates

In the most recent fiscal year, Boston Scientific reported gross margin of 69%, EBITDA margin of 25%, and net margin of 14%.

See estimated margins and future growth rates for Boston Scientific

Boston Scientific Margins

Last FY20242025202720282029
Gross Margin69%69%69%
EBITDA Margin25%23%25%
EBIT Margin20%18%20%
Net Margin14%11%14%
FCF Margin17%14%17%

Boston Scientific Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth18%20%
Gross Profit Growth16%21%
EBITDA Growth12%32%
EBIT Growth24%32%
Net Profit Growth16%56%
FCF Growth39%44%

Data powered by FactSet, Inc. and Morningstar, Inc.

Boston Scientific Operational KPIs

Boston Scientific's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.

Access forward-looking KPIs for Boston Scientific
LTMLast FY202320242025202620272028
Rule of 4040%
Bessemer Rule of X52%
Revenue per Employee$0.3M
Opex per Employee$0.2M
S&M Expenses to Revenue33%
R&D Expenses to Revenue10%10%10%10%10%
Opex to Revenue49%53%51%49%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Boston Scientific Competitors

Boston Scientific competitors include Medtronic, Stryker, Edwards Lifesciences, Siemens Healthineers, IDEXX Laboratories, Danaher, Alcon, Waters, Agilent and Mindray.

Most Boston Scientific public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Medtronic3.6x3.3x13.0x11.8x
Stryker5.0x4.8x19.8x16.9x
Edwards Lifesciences7.3x7.0x30.5x23.1x
Siemens Healthineers1.6x1.6x8.1x7.9x
IDEXX Laboratories10.6x10.3x30.2x29.1x
Danaher5.6x5.5x19.6x17.4x
Alcon3.8x3.8x14.8x14.7x
Waters12.1x8.9x37.3x26.2x

This data is available for Pro users. Sign up to see all Boston Scientific competitors and their valuation data.

Start Free Trial

Boston Scientific M&A Activity

Boston Scientific has acquired 42 companies to date.

Last acquisition by Boston Scientific was on January 15th 2026. Boston Scientific acquired Penumbra for $15B (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by Boston Scientific

Penumbra
Valencia Technologies
Nalu Medical
Elutia (bioenvelope unit)
Description
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
Valencia Technologies is a medical device company developing neuromodulation therapies for overactive bladder. Nashville-headquartered, it commercializes the eCoin peripheral tibial nerve stimulator, FDA-approved in 2022 for urge urinary incontinence. The coin-sized implant delivers six months of automated stimulation without batteries, wires, or recharging, via a 20-minute office procedure under local anesthesia. Over 1,000 patients treated show sustained symptom relief at 36 months, with coverage by Medicare and major insurers.
Nalu Medical is a Carlsbad-headquartered medtech company offering implantable neurostimulation systems for chronic pain relief via spinal cord stimulation and peripheral nerve stimulation. Its micro-IPG features a battery-free design powered by an external Therapy Disc, with FDA clearances for both indications, smartphone app control, and software waveforms. A compact Therapy Disc version enhances comfort for peripheral applications.
HQ CountryUnited StatesUnited StatesUnited StatesUnited States
HQ City
San Francisco, CA
San Diego, CA
Deal Date15 Jan 202612 Jan 202617 Oct 20259 Sep 2025
Valuation$15Bundisclosed$533M$88M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Boston Scientific acquisitions and their M&A valuation multiples.

Start Free Trial

Boston Scientific Investment Activity

Boston Scientific has invested in 19 companies to date.

Latest investment by Boston Scientific was on March 5th 2025. Boston Scientific invested in 4C Medical Technologies in their $175M Series D round (EV/Revenue multiple of ).

See VC round multiples

Latest Investments by Boston Scientific

4C Medical Technologies
Nectero Medical
Nectero Medical
Append Medical
Description
4C Medical Technologies is a medical device company developing transcatheter mitral valve replacement systems for structural heart disease. Minneapolis-based, its Altis device anchors in the left atrium to preserve native valve anatomy and ventricular function. Incorporated in 2015, the firm has completed first-in-human implants in Europe and holds FDA Breakthrough Device Designation.
Nectero Medical is a Dover, Delaware-headquartered developer of endovascular therapies for cardiovascular diseases. Its lead product, the Nectero EAST system, delivers a one-time infusion to halt progression and stabilize small to mid-sized abdominal aortic aneurysms measuring 3.5 to 5.0 centimeters. Founded in 2017, the company completed Phase I/IIa trials in 2023 with positive safety data from 30 patients and holds FDA Breakthrough Device Designation for accelerated review.
Nectero Medical is a Dover, Delaware-headquartered developer of endovascular therapies for cardiovascular diseases. Its lead product, the Nectero EAST system, delivers a one-time infusion to halt progression and stabilize small to mid-sized abdominal aortic aneurysms measuring 3.5 to 5.0 centimeters. Founded in 2017, the company completed Phase I/IIa trials in 2023 with positive safety data from 30 patients and holds FDA Breakthrough Device Designation for accelerated review.
Append Medical is a Herzliya-based medtech company developing the Laminar Left Atrial Appendage Closure device for stroke prevention in atrial fibrillation patients. The transcatheter implant undergoes preclinical in-vivo trials, positioning it in the rapidly expanding LAA closure segment. As a member of the MEDX Xelerator incubator in Tel Aviv, backed by Boston Scientific and Sheba Medical Center, Append Medical advances differentiated solutions for cardiac interventions.
HQ CountryUnited StatesUnited StatesUnited StatesIsrael
HQ City
Tempe, AZ
Tempe, AZ
Or Yehuda
Deal Date5 Mar 202511 Apr 202410 Sep 20214 Aug 2021
RoundSeries DSeries DSeries CSeries A
Raised$175M$96M$20M$7M
InvestorsBoston Scientific; Fu Yuan InvestmentAlumni Ventures; Aphelion Capital; BioStar Capital; Boston Scientific; Cadence Healthcare Ventures; NorwestBoston Scientific; KOFA HealthcareBoston Scientific; Intellectual Ventures; MEDX Xelerator
Valuationundisclosedundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Boston Scientific investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Boston Scientific

When was Boston Scientific founded?Boston Scientific was founded in 1979.
Where is Boston Scientific headquartered?Boston Scientific is headquartered in United States.
How many employees does Boston Scientific have?As of today, Boston Scientific has over 59K employees.
Who is the CEO of Boston Scientific?Boston Scientific's CEO is Michael F. Mahoney.
Is Boston Scientific publicly listed?Yes, Boston Scientific is a public company listed on NYSE.
What is the stock symbol of Boston Scientific?Boston Scientific trades under BSX ticker.
When did Boston Scientific go public?Boston Scientific went public in 1992.
Who are competitors of Boston Scientific?Boston Scientific main competitors include Medtronic, Stryker, Edwards Lifesciences, Siemens Healthineers, IDEXX Laboratories, Danaher, Alcon, Waters, Agilent, Mindray.
What is the current market cap of Boston Scientific?Boston Scientific's current market cap is $83B.
What is the current revenue of Boston Scientific?Boston Scientific's last 12 months revenue is $21B.
What is the current revenue growth of Boston Scientific?Boston Scientific revenue growth (NTM/LTM) is 8%.
What is the current EV/Revenue multiple of Boston Scientific?Current revenue multiple of Boston Scientific is 4.5x.
Is Boston Scientific profitable?Yes, Boston Scientific is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of Boston Scientific?Boston Scientific's last 12 months EBITDA is $6B.
What is Boston Scientific's EBITDA margin?Boston Scientific's last 12 months EBITDA margin is 31%.
What is the current EV/EBITDA multiple of Boston Scientific?Current EBITDA multiple of Boston Scientific is 14.4x.
What is the current FCF of Boston Scientific?Boston Scientific's last 12 months FCF is $4B.
What is Boston Scientific's FCF margin?Boston Scientific's last 12 months FCF margin is 18%.
What is the current EV/FCF multiple of Boston Scientific?Current FCF multiple of Boston Scientific is 24.8x.
How many companies Boston Scientific has acquired to date?As of May 2026, Boston Scientific has acquired 42 companies.
What was the largest acquisition by Boston Scientific?$15B acquisition of Penumbra on 15th January 2026 was the largest M&A Boston Scientific has done to date.
What companies Boston Scientific acquired?Boston Scientific acquired Penumbra, BTG International, Axonics Modulation Technologies, Baylis Medical Company, American Medical Systems, Preventice Solutions, Silk Road Medical, LUMENIS (surgical unit), Relievant Medsystems, Acotec Scientific Hldgs, and 32 other companies.
In how many companies Boston Scientific has invested to date?As of May 2026, Boston Scientific has invested in 19 companies.
What was the last Boston Scientific investment?On 5th March 2025 Boston Scientific invested in 4C Medical Technologies, participating in a $175M Series D round, alongside Fu Yuan Investment.
In what companies Boston Scientific invested in?Boston Scientific invested in 4C Medical Technologies, Preventice Solutions, Nectero Medical, Saluda Medical, Pulmonx, NxThera, Amphora Medical, SetPoint Medical, BAROnova, NeuroTronik, Channel Medsystems, Sensible Medical Innovations, Neuros Medical, InterVene, TVA Medical, Securus Medical Group, RenovoRx, Append Medical, and Millipede.

See public comps similar to Boston Scientific

Lists including Boston Scientific

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial